Pune: The Serum Institute of India (SII) will begin production of Russia’s Sputnik V in September and it is intended to produce over 300 million doses of the vaccine in India per year, said Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund). Earlier in the day, RDIF and SII also announced their cooperation to produce the Russian Sputnik vaccine against coronavirus.Also Read – US Says it’s Ready to Ship Pfizer, Moderna Vaccines, But Waiting for India’s Green Light

Speaking on the improvement, Dmitriev said, “RDIF is delighted to cooperate with Serum Institute of India, the world’s largest vaccine manufacturer. This strategic partnership is a major step to substantially increase our production capabilities demonstrating a perfect example of joining forces and expertise to save lives both in India and around the world. With technology transfer underway we expect the first batches of the vaccine to be produced jointly with SII in coming months.” Also Read – Govt Warns Covid Violators, Says Don’t Talk About Third Wave Like Weather Update, Understand The Seriousness

SII CEO Adar Poonawalla also commented on this and said, “I am delighted to partner with RDIF to manufacture the Sputnik vaccine. We hope to make millions of doses in the coming months with trial batches starting in the month of September. With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world. Given the uncertainty of the virus, it is important for international institutes, and governments to collaborate and further bolster up our fight against the pandemic.” Also Read – Puducherry Unlock: Govt Allows Restarting of Regular Classes for Medical and Paramedical Courses

An official statement released on the process read, “As part of the technical transfer process, SII has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun. India is the leading production hub for production of Sputnik vaccine. RDIF had earlier reached agreements with a number of pharmaceutical companies in India (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen) for production of the Russian vaccine.”

To date, Russian Sputnik V vaccine has been registered in 67 countries globally with a total population of over 3.5 bn people. The data obtained by regulators of a number of countries during the vaccination of the population, including in Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus, added the statement.